NSSG Chemotherapy Protocol
benefit-risk assessment of Imatinib, and patient's preference [NICE TA70] Licensed / unfunded indication NICE does not recommend high-dose Imatinib for the treatment of chronic, accelerated or blast-crisis phase Philadelphia-chromosome-positive CML that is …
Download NSSG Chemotherapy Protocol
Information
Domain:
Source:
Link to this page:
Documents from same domain
CYCLOPHOSPHAMIDE / BORTEZOMIB/ …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed of MM.11 CyBorDex- Amyloidosis Authorised by …
Cyclophosphamide priming prior to PBSC harvest
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology Oxford BMT Programme B.2.20b Page 1 of 3 May 2017 V.5.4 Cyclo prime for Myeloma PSBC Harvest Authorised by: Dr Karthik Ramasamy
ATTENUATED CYCLOPHOSPHAMIDE, THALIDOMIDE & …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed MM.9 CTD - attenuated Authorised by Myeloma lead Dr. Karthik Ramasamy July 2017
Guidelines for the Management of Hypomagnesaemia …
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology H.95 Page 2 of 5 November 2015 V.1.0. Guidelines for the management of hypomagnesaemia in Adult Clinical Haematology
Oxford Myeloma Group
nssg.oxford-haematology.org.ukMM.50 VTDPACE/DTPACE Authorised by Myeloma lead Dr. Karthik Ramasamy June 2022 V. 2.0 of 10 Days Drug Dose Route Comments 1 to 4 Dexamethasone 40 mg daily Oral Continuous daily/ If PBSC harvest planned only for days 1 to 4 Thalidomide (See note below) Start 50 mg and increase up to 100 mg as tolerated Oral Nocte 1 to 4
MATRix (High dose METHOTREXATE, high dose CYTARABINE ...
nssg.oxford-haematology.org.uk- Reduce thiotepa dose to 75% - Reduce methotrexate to 2g/m2 Haematological toxicity In case if inadequate bone marrow recovery (i.e. neutrophils < 1.5x109/L and platelets < 90x109/L on the intended day of re-treatment, delay cycle until counts satisfactory. Doses of the chemotherapy
ISATUXIMAB WITH POMALIDOMIDE AND …
nssg.oxford-haematology.org.ukvolume Initial rate Absence of infusion reaction Rate increment Maximum rate First infusion 250 mL 25 mL/ hour For 60 minutes 25 mL/hour every 30 minutes 150 mL/ hour Second infusion 250 mL 50 mL/ hour For 30 minutes 50 mL/ hour for 30 minutes then increase by 100 mL/ hr every 30 minutes 200 mL/ hour Subsequent infusions
ATRA + ARSENIC TRIOXIDE
nssg.oxford-haematology.org.ukArsenic Trioxide infusion duration may be extended up to 4 hours if vasomotor reactions, e.g. flushing, tachycardia and dizziness, are observed. If patients suffer severe symptoms or hypotension then the infusion should be stopped until recovery and then recommenced at a
High dose METHOTREXATE (high grade NHL CNS …
nssg.oxford-haematology.org.ukadults receiving high-dose methotrexate chemotherapy (doses >1g/m2) - Who develop significant deterioration in renal function (>1.5x ULN and rising, or the presence of oliguria) OR - Have toxic plasma methotrexate level AND - Have been treated with all standard rescue and supportive measures AND
ESHAP and R-ESHAP
nssg.oxford-haematology.org.uk2. Record stage of disease - contrast enhanced CT scan (neck, chest, abdomen and pelvis), ... In order to eliminate the risk of transmitting infective ... After 1-2 cycles with CT or PET-CT. Lymphoma group This is a controlled document and therefore must …
Related documents
HAZARD IDENTIFICATION & RISK ASSESSMENT (HIRA)
rlsdhamal.comAssess and score the risk (i.e. probability X severity) using the Risk Matrix as per TPL Risk Assessment Matrix (RAM) (refer to Section 6.3). List out present controls (preventive and recovery). Assess the risk based on present controls. Reassess the medium and high risk to bring it down to acceptable risk.
ISATUXIMAB WITH POMALIDOMIDE AND …
nssg.oxford-haematology.org.ukREGIMENSPECIFIC PRE-ASSESMENT 1. Ensure patients are given a Patient ID Card for isatuximab and are instructed to carry this for 6 months after stopping treatment. 2. Advise patients to inform their other HCPs that they have received isatuximab, particularly before a transfusion and to show their patient ID card to healthcare professionals that ...
BIOLOGY INTERNAL ASSESMENT HIGHER LEVEL
cpb-us-w2.wpmucdn.comexperiment, the wavelengths of light at which the tissue won’t be at risk (the wavelength range of visible light) and at which the bacteria growth is inhibited or stopped can be found. Feursteinet et al found that blue light at 400 – 500 nm exerts a phototoxic effect on some strains of bacteria.
POLYVINYL ALCOHOL (PVA) - Food and Agriculture …
www.fao.orgFinal report on the safety assesment of Polyvinyl alcohol- safety assesment of cosmetic ingredients (36th report of the cosmetic ingredient review Expert panel0. Int J Toxicol 17(Suppl. 5):67-92. CIR. 1998. Vinyl acetate, polyvinyl acetate and Polyvinyl alcohol. In: Some Monomers, Plastics, and Synthetic Elastomers, and Acrolein.
Recommendations for Businesses with COVID-19 Positive ...
www.maine.govRecommendations for Businesses with COVID-19 Positive Individuals: Maine CDC may not follow up individually with every person who tests positive in Maine.
HAND ARM VIBRATION & DECIBEL RATING - Hire Equip
www.hireequip.co.ukCan be used for upto two hours a day, over this point risk assesment required Risk access, significant chance of injury without proper monitoring Hearing protection should be made readily available, use of is advised.
Opioid Risk Tool - National Institute on Drug Abuse
nida.nih.govOpioid Risk Tool Introduction he Opioid Risk Tool (ORT) is a brief, self-report screening tool designed for use with adult patients in primary care settings to assess risk for opioid abuse among individuals prescribed opioids for treatment of chronic pain.
A GUIDE TO STRATEGIC ENVIRONMENTAL ASSESSMENT
unece.organd those potentially imposed to the risk of hazard. After the discussion, the full set of information should be presented to decision makers or bodies, which should consider the benefits of the proposed activities and compare it to the potential environmental damage, and